AmerisourceBergen Specialty Group – ABSG

For pharmaceutical manufacturers and healthcare providers, AmerisourceBergen Specialty Group is an essential business partner. We lead the market in biotechnology, plasma derivative and oncology product distribution. Pharmaceutical manufacturers rely on us for services like outsourced logistics and market access programs that support commercialization strategies. We provide the resources physicians need to maximize practice efficiency and the specialty pharmacy services patients need to improve their health.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.wpv-pagination-nav-links[data-toolset-views-view-pagination-block="33746bd812994fc2d16011719be6c6d7"] { text-align: left;justify-content: flex-start; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] { text-align: center; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__link { background-color: rgba( 6, 147, 227, 1 );font-size: 16px;font-weight: bold; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__link:hover { background-color: rgba( 142, 209, 252, 1 );border-radius: 5px; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__icon { font-family: dashicons;margin-left: 8px; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__icon::before { content: '\f465'; }   .tb-field[data-toolset-blocks-field="2352d76bb895ac4d7e6623b3996ba2ab"] { font-weight: bold; }  .tb-fields-and-text[data-toolset-blocks-fields-and-text="be25192e3b17b888e76f432f0e43e989"] { background-color: rgba( 142, 209, 252, 1 );padding-top: 5px;padding-bottom: 5px; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="03586fe69ea5b5174ebf265d564b8feb"] { padding: 0px 0px 5px 0px;margin-bottom: 10px;border-bottom: 2px solid rgba( 204, 203, 203, 1 ); } h3.tb-heading[data-toolset-blocks-heading="993a682c67afb3c5e9ef718484910c20"]  { font-size: 16px;color: rgba( 0, 51, 153, 1 );padding-bottom: 5px; }  @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .tb-container .tb-container-inner{width:100%;margin:0 auto}  } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .tb-container .tb-container-inner{width:100%;margin:0 auto}  } 

Company Details

AmerisourceBergen Specialty Group – ABSG

3101 Gaylord Parkway, Frisco, TX, 75034, United States

+1 866-408-3761

Website

My Dad was ‘one in a million’, as the saying goes. But actually he was one in 300 million (of patients worldwide with rare disease)

White Papers and Resources | February 29, 2020 | OPEN Health

Emily Wigginton, Client Services Director, OPEN Health Patient & Brand Communications

AmerisourceBergen Specialty Group – ABSG

13th Edition – Spring MEDAFFAIRS Leaders Forum

HARNESSING TECHNOLOGY TO TRANSFORM HEALTHCARE IN THE DIGITAL AGE

Mergers and acquisitions: agents for change

Keeping calm and carrying on: COVID-19 and approaches to CME/CPD during a viral outbreak

Promoting enthusiasm and scientific expertise at Porterhouse Medical

Top 10 Most Important Advisor Questions

Four Health announces a pair of internal promotions

Meet two of OPEN Health’s practices – Peloton Advantage and Pharmerit at MAPS 2020

Porterhouse Medical Group strengthens its leadership team in the US

My Dad was ‘one in a million’, as the saying goes. But actually he was one in 300 million (of patients worldwide with rare disease)